Back
About
SAGIMET BIOSCIENCES is a clinical-stage biopharmaceutical company that develops new therapeutic agents called fatty acid synthase inhibitors.
The company does not yet have any approved drugs for use in the US and EU. However, SAGIMET BIOSCIENCES' drugs are currently in clinical trials and have already shown promising results in a group of 600 people.
The company plans to offer 4.69 million shares at a price ranging from $15.00 to $17.00 to raise $75.0 million.
__________________________________________
Number of employees:
10
___________________________________________
Headquarters:
155 Bovet Road, Suite 303 San Mateo, California 94402
Calls within Tajikistan are free
Investments
Information
The information provided is for informational purposes only and should not be considered as an offer to buy or sell foreign currency, securities and/or other financial instruments. The information presented on this website is not an individual investment recommendation. Financial instruments or transactions mentioned in this section may not be suitable for you, may not correspond to your investment profile, financial situation, investment experience, knowledge, investment objectives, attitude to risk and profitability.
LLC "Exchange Broker" does not guarantee and does not promise future profitability of investments, does not guarantee the reliability of possible investments and the stability of possible income. Investment results in the past do not guarantee income in the future.
LLC "Exchange Broker" is not responsible for possible investor losses in the event of transactions and investments in financial instruments, and also does not guarantee the return, effectiveness and profitability of investments.
LLC "Exchange Broker" hereby informs that it operates in the securities market in accordance with the following professional participant licenses issued by the Ministry of Finance of the Republic of Tajikistan: depository activity No.010/25 dated 25.06.2025; brokerage activity No.007/25 dated 25.06.2025; dealer activity No.008/25 dated 25.06.2025 and securities management activity No.009/25 dated 25.06.2025, and also informs about the risk of a conflict of interest, including as a result of combining various types of professional activity in the securities market.